Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 26, 2003. The report details a specific corporate action regarding share re-purchases executed on March 25, 2003, pursuant to shareholder authority granted at the Annual General Meeting on May 20, 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 850,000 ordinary shares
- Purchase Price: 1164.24p per share
- Transaction Date: March 25, 2003
- Use of Proceeds: Shares were purchased for cancellation
Material Changes
The filing does not report material changes in operating results or financial position compared to prior periods. The primary change reported is the reduction of the company's share capital through the cancellation of 850,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine disclosure of a capital management activity.
Key Facts for Investor Verification
- Verify the total number of shares authorized for re-purchase under the May 20, 2002 shareholder resolution to determine remaining capacity.
- Confirm the total cost of the transaction (850,000 shares x 1164.24p) against the company's cash reserves in the most recent full financial report.
- Check subsequent filings to see if the company has continued its share buyback program beyond this specific transaction.